JSP191 is well tolerated with no treatment-related severe adverse events in 17 subjects with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in Ph1b dose expansion study 17 of 17 subjects achieved successful engraftment with neutrophil recovery 12 of 15 subjects with measurable